Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.67 |
| ▸ | FAP | Q12884 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23932601 | 1.00 | CYP3A4 (0.83) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL29355255 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL18894359 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| SCHEMBL20302999 | 0.91 | CYP3A4 (0.79) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL2040329 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| SCHEMBL18502993 | 0.91 | CYP3A4 (0.79) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL497725 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL39724 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL3133933 | 0.90 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| SCHEMBL24721830 | 0.90 | CYP3A4 (0.85) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159574-A1 | BENZYLOXY PHOSPH(ON)ATE COMPOUNDS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-05-25 | — | — | US | disclosed |
| EP-4139319-A1 | BENZYLOXY PHOSPH(ON)ATE COMPOUNDS | Ligand Pharmaceuticals, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021216431-A1 | BENZYLOXY PHOSPH(ON)ATE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159574-A1 | BENZYLOXY PHOSPH(ON)ATE COMPOUNDS | PYGL, GOT2, ALPI | CYP3A4 1046/4885CYP2D6 1408/4885FAP 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.